ClinicalTrials.gg
CompletedNCT00267254Updated Nov 21, 2007

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.

A Phase 3 interventional study of torcetrapib/atorvastatin and simvastatin in Hyperlipidemia, Dyslipidemia and Hypercholesterolemia, sponsored by Pfizer. Completed at 49 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-11-21.

Primary conditionHypercholesterolemiaRegistry: HyperlipidemiasReclassifiedWhy we changed it
Registry
Hyperlipidemias — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypercholesterolemia
Why
  1. The study's listed conditions name Hypercholesterolemia, a narrower term within Hyperlipidemias.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
640
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.

Enrollment
16th of 75
640 · median 148
Started
2006
with 1 other
Phase 3
31 of 77
none open now
Registered
14th of 77
by date

Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 16th largest by enrollment of the 75 interventional ones that give a count, is one of 2 that started in 2006, is one of 31 in phase 3, and was the 14th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies testing atorvastatin in Hypercholesterolemia, or all of them as a file.
02

Study summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of cholesterol medications to see how the different treatments compare to one another.

Read the detailed description

For additional information please call: 1-800-718-1021

03

Conditions studied

  • Hyperlipidemia
  • Dyslipidemia
  • Hypercholesterolemia

Browse trials for

04

In context

Hypercholesterolemia Reclassified

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

This study's enrollment of 640 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.

Browse Hypercholesterolemia studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hyperlipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • eligible for statin treatment for LDL cholesterol by NCEP guidelines

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating, or planning to become pregnant.
  • Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors.
  • Subjects with significant liver or kidney disease or significant heart failure.
06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
640 participants

Interventions

07

What researchers measure

Primary outcomes

  1. Percent change in LDL-C and HDL-C from baseline, after six weeks of treatment.

Secondary outcomes

  1. Changes in other lipid parameters and other biomarkers.

08

Study locations

49 sites
  • Pfizer Investigational Site
    Birmingham, Alabama, United States
  • Pfizer Investigational Site
    Mobile, Alabama, United States
  • Pfizer Investigational Site
    Mesa, Arizona, United States
  • Pfizer Investigational Site
    Phoenix, Arizona, United States
  • Pfizer Investigational Site
    Tempe, Arizona, United States
  • Pfizer Investigational Site
    Little Rock, Arkansas, United States
  • Pfizer Investigational Site
    Los Angeles, California, United States
  • Pfizer Investigational Site
    San Diego, California, United States
  • Pfizer Investigational Site
    Santa Rosa, California, United States
  • Pfizer Investigational Site
    Boynton Beach, Florida, United States
  • Pfizer Investigational Site
    Melbourne, Florida, United States
  • Pfizer Investigational Site
    Merritt Island, Florida, United States
  • Pfizer Investigational Site
    Palm Bay, Florida, United States
  • Pfizer Investigational Site
    Safety Harbor, Florida, United States
  • Pfizer Investigational Site
    Tampa, Florida, United States
  • Pfizer Investigational Site
    Chicago, Illinois, United States
  • Pfizer Investigational Site
    Newton, Kansas, United States
  • Pfizer Investigational Site
    Topeka, Kansas, United States
  • Pfizer Investigational Site
    Wichita, Kansas, United States
  • Pfizer Investigational Site
    Madisonville, Kentucky, United States
  • Pfizer Investigational Site
    Boston, Massachusetts, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan, United States
  • Pfizer Investigational Site
    Canton, Michigan, United States
  • Pfizer Investigational Site
    Portage, Michigan, United States
  • Pfizer Investigational Site
    Troy, Michigan, United States
  • Pfizer Investigational Site
    Minneapolis, Minnesota, United States
  • Pfizer Investigational Site
    Kansas City, Missouri, United States
  • Pfizer Investigational Site
    St. Louis, Missouri, United States
  • Pfizer Investigational Site
    Butte, Montana, United States
  • Pfizer Investigational Site
    Lincoln, Nebraska, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada, United States
  • Pfizer Investigational Site
    Concord, New Hampshire, United States
  • Pfizer Investigational Site
    Trenton, New Jersey, United States
  • Pfizer Investigational Site
    Cooperstown, New York, United States
  • Pfizer Investigational Site
    East Syracuse, New York, United States
  • Pfizer Investigational Site
    Rochester, New York, United States
  • Pfizer Investigational Site
    Charlotte, North Carolina, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio, United States
  • Pfizer Investigational Site
    Clinton, South Carolina, United States
  • Pfizer Investigational Site
    Cordova, Tennessee, United States
  • Pfizer Investigational Site
    Memphis, Tennessee, United States
  • Pfizer Investigational Site
    Milan, Tennessee, United States
  • Pfizer Investigational Site
    Dallas, Texas, United States
  • Pfizer Investigational Site
    Fort Worth, Texas, United States
  • Pfizer Investigational Site
    San Antonio, Texas, United States
  • Pfizer Investigational Site
    Payson, Utah, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah, United States
  • Pfizer Investigational Site
    Norfolk, Virginia, United States
  • Pfizer Investigational Site
    Milwaukee, Wisconsin, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2005
First posted
Dec 20, 2005
Start
Jan 2006
CompletionActual
Aug 2006
Last update
Nov 21, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00267254
Lead sponsor
Pfizer
First posted
Dec 20, 2005
Start date
Jan 2006
Completion
Aug 2006
Last update
Nov 21, 2007

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Torcetrapib · Atorvastatin · Simvastatin

Start the discussion